文献速递白血病

细胞遗传学缓解对急性髓系白血病长期生存的影响

Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.
PubMed 文献 · Am J Hematol · 2025-07-11

该回顾性研究纳入克利夫兰诊所2017年5月至2023年9月治疗的973例成人急性髓系白血病患者,其中563例有基线细胞遗传学数据及治疗后反应评估。按基线与缓解后细胞遗传学状态分组,采用界标分析,中位随访45.8个月,评估不同细胞遗传学缓解水平对总生存和无事件生存的影响。

要点

  • 基线正常且治疗后维持正常者中位OS为37个月(95%CI:27-91),为参照组。
  • 基线异常持续异常者中位OS为13个月(95%CI:12-18),HR=1.61(95%CI:1.13-2.31)。
  • 实现完全或部分细胞遗传学缓解与更好的生存结局相关。

核心结论

  • 实现完全或部分细胞遗传学缓解与更好的生存结局相关。
  • 这些发现强调监测细胞遗传学反应对指导治疗决策的重要性,并支持将细胞遗传学反应整合入风险适配的个体化急性髓系白血病管理策略。

研究设计与样本

  • 回顾性研究,纳入克利夫兰诊所2017年5月至2023年9月治疗的973例成人急性髓系白血病患者。
  • 563例患者有基线细胞遗传学数据及治疗后反应评估可用。
  • 采用界标分析处理治疗后评估。

主要发现

  • 队列中位年龄62岁(四分位距:52-69),女性256例(45%),90%为白人,中位随访45.8个月(范围:0.73-191.3)。
  • 正常至正常组(n=221,39%)中位OS为37个月(95%CI:27-91),HR为参照。
  • 正常或异常至获得组(n=46,8.2%)中位OS为14个月(95%CI:8.6-30),HR=1.5(95%CI:0.99-2.39)。
  • 异常至持续组(n=81,14%)中位OS为13个月(95%CI:12-18),HR=1.61(95%CI:1.13-2.31)。
  • 异常至部分缓解组(n=20,3.6%)中位OS为25个月(95%CI:14-NC),HR=0.76(95%CI:0.39-1.49);异常至完全缓解组(n=195,35%)中位OS为27个月(95%CI:19-101),HR=1.25(95%CI:0.93-1.68);p=0.038。

临床怎么用

  • 原文结论指出,这些发现强调监测细胞遗传学反应对指导治疗决策的重要性,并支持将细胞遗传学反应整合入风险适配的个体化急性髓系白血病管理策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event-free survival (EFS) in AML. Among 973 adult AML patients treated at Cleveland Clinic (5/2017-9/2023), 563 patients had baseline cytogenetic data and post-treatment response assessment available. Based on baseline and response cytogenetic status, patients were categorized into: normal to normal (NL-Cy to NL-Cy, n = 221, 39%), normal or abnormal to gain (NL/Abnl-Cy to Gain-Cy, n = 46, 8.2%), abnormal to persistent (Abnl-Cy to Persistent-Cy, n = 81, 14%), abnormal to partial response (Abnl-Cy to Partial-Cy, n = 20, 3.6%), and abnormal to complete response (Abnl-Cy to NL-Cy, n = 195, 35%). Landmark analysis was used to account for post-treatment assessments. The cohort had a median age of 62 years (interquartile range: 52-69), 256 females (45%), 90% were White, and median follow-up of 45.8 months (range: 0.73-191.3). The median OS and hazard ratios (HRs) from multivariable regression analysis were as follows: NL-Cy to NL-Cy: 37 months (95% CI: 27-91), HR = reference; NL/Abnl-Cy to Gain-Cy: 14 months (95% CI: 8.6-30), HR = 1.5 (95% CI: 0.99-2.39); Abnl-Cy to Persistent-Cy: 13 months (95% CI: 12-18), HR = 1.61 (95% CI: 1.13-2.31); Abnl-Cy to Partial-Cy: 25 months (95% CI: 14-NC), HR = 0.76 (95% CI: 0.39-1.49); and Abnl-Cy to NL-Cy: 27 months (95% CI: 19-101), HR = 1.25 (95% CI: 0.93-1.68) (p = 0.038). Achieving cytogenetic remission, complete or partial, was associated with better survival outcomes. These findings highlight the importance of monitoring cytogenetic responses to inform treatment decisions and support integrating cytogenetic response into risk-adapted, personalized AML management strategies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hanna J, Zabor EC, Albliwi M, et al. Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia. Am J Hematol. 2025. PMID: 40642970. doi:10.1002/ajh.70000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。